RCAG
VRTX icon

Rehmann Capital Advisory Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Rehmann Capital Advisory Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$910K Buy
2,039
+102
+5% +$47.6K 0.05% 266
2025
Q4 		$879K Buy
1,937
+61
+3% +$26.3K 0.05% 269
2025
Q3 		$735K Buy
1,876
+168
+10% +$70.2K 0.04% 299
2025
Q2 		$760K Buy
1,708
+144
+9% +$66.4K 0.05% 268
2025
Q1 		$758K Buy
1,564
+48
+3% +$22.4K 0.05% 267
2024
Q4 		$610K Sell
1,516
-436
-22% -$202K 0.04% 305
2024
Q3 		$906K Sell
1,952
-747
-28% -$359K 0.06% 228
2024
Q2 		$1.27M Sell
2,699
-81
-3% -$35.2K 0.09% 172
2024
Q1 		$1.16M Buy
2,780
+282
+11% +$119K 0.09% 185
2023
Q4 		$1.02M Buy
2,498
+290
+13% +$107K 0.08% 188
2023
Q3 		$768K Hold
2,208
– – 0.07% 214
2023
Q2 		$777K Sell
2,208
-361
-14% -$122K 0.07% 230
2023
Q1 		$809K Sell
2,569
-27
-1% -$8.1K 0.08% 226
2022
Q4 		$750K Buy
2,596
+68
+3% +$20.7K 0.08% 224
2022
Q3 		$732K Buy
2,528
+220
+10% +$63.3K 0.08% 216
2022
Q2 		$650K Sell
2,308
-492
-18% -$132K 0.07% 234
2022
Q1 		$745K Buy
2,800
+392
+16% +$93K 0.07% 247
2021
Q4 		$529K Sell
2,408
-165
-6% -$32.1K 0.05% 305
2021
Q3 		$466K Sell
2,573
-81
-3% -$15.8K 0.04% 335
2021
Q2 		$502K Buy
2,654
+551
+26% +$115K 0.05% 307
2021
Q1 		$451K Buy
2,103
+279
+15% +$61.3K 0.05% 305
2020
Q4 		$431K Sell
1,824
-204
-10% -$46.8K 0.05% 295
2020
Q3 		$552K Buy
2,028
+109
+6% +$30.1K 0.07% 229
2020
Q2 		$557K Buy
1,919
+398
+26% +$108K 0.08% 221
2020
Q1 		$362K Buy
+1,521
New +$349K 0.06% 251
2019
Q3 		$330K Buy
1,949
+1,509
+343% +$267K 0.04% 238
2019
Q2 		$80.7K Sell
440
-1
-0.2% -$175 0.01% 683
2019
Q1 		$81.1K Buy
441
+32
+8% +$5.91K 0.01% 659
2018
Q4 		$67.8K Buy
409
+75
+22% +$13K 0.01% 504
2018
Q3 		$64.4K Sell
334
-42
-11% -$7.48K 0.01% 712
2018
Q2 		$63.9K Sell
376
-1,022
-73% -$158K 0.01% 698
2018
Q1 		$228K Buy
+1,398
New +$228K 0.04% 342

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Rehmann Capital Advisory Group's VRTX Position: Q1 2026 in Review

Rehmann Capital Advisory Group increased its Vertex Pharmaceuticals (VRTX) stake by 5.3% in Q1 2026, buying an estimated $47.6K and bringing the position to 2,039 shares worth $910K. The position accounts for 0.05% of the portfolio, ranked #266.

Rehmann Capital Advisory Group first reported a position in VRTX in Q1 2018 and has held it in 32 quarters since. The position peaked at $1.27M in Q2 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Rehmann Capital Advisory Group held 2,039 shares of Vertex Pharmaceuticals worth $910K as of Q1 2026.
  • Rehmann Capital Advisory Group bought 102 Vertex Pharmaceuticals shares in Q1 2026, an estimated $47.6K.
  • Vertex Pharmaceuticals made up 0.05% of Rehmann Capital Advisory Group's portfolio in Q1 2026, its #266 holding.
  • Rehmann Capital Advisory Group first reported a position in Vertex Pharmaceuticals in Q1 2018 and has held it in 32 quarters since.
  • Rehmann Capital Advisory Group's Vertex Pharmaceuticals position peaked at $1.27M in Q2 2024.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Rehmann Capital Advisory Group's 13F filing for Q1 2026, filed 15 May 2026.